Biotech IPOs: It's just a flesh wound

VC blogger Bruce Booth turns to Monty Python's Holy Grail to help illustrate his thoughts on the ever-elusive biotech IPO. The IPO is not dead, but it has been bloodily hacked up. Looking back on 23 biotech IPOs, Booth finds that the group stock price dropped a collective 17%, with 61% trading below their initial price. Among the poorest performers: Tengion, Alimera, Pacific Biosciences and NuPathe, which all plunged more than 80%. Bright spots include AVEO and Aegerion. Column